Imunon (NASDAQ:IMNN) Receives “Buy” Rating from HC Wainwright

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $12.00 price target on the stock.

A number of other analysts also recently issued reports on the stock. EF Hutton Acquisition Co. I raised shares of Imunon to a “strong-buy” rating in a report on Monday, September 23rd. D. Boral Capital reiterated a “buy” rating and issued a $29.00 price objective on shares of Imunon in a research report on Thursday.

Imunon Trading Down 2.8 %

Shares of NASDAQ:IMNN opened at $0.83 on Thursday. Imunon has a 12-month low of $0.48 and a 12-month high of $3.65. The business has a 50 day moving average of $0.87 and a two-hundred day moving average of $1.07. The company has a market capitalization of $12.04 million, a PE ratio of -0.44 and a beta of 2.12.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.